Bisena Bulica
Neurology · Detroit, MINPI 1093152019
Payments from drug & device makers
Across 1,908 payments — averaging $756.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$583K
- Genentech, Inc.$428K
- Teva Pharmaceuticals USA, Inc.$212K
- Roche TCRC, Inc.$89K
- Acadia Pharmaceuticals Inc$35K
- Grifols, S.A.$24K
- plus $72K from 27 others
What the payments were for
- Consulting fees$129,01814%
- Speaking & faculty fees$610,30168%
- Travel & lodging$107,69612%
- Food & beverage$51,1256%
- Education$2,2070%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 992 | $583,294 |
| Genentech, Inc. | 16 | $428,064 |
| Teva Pharmaceuticals USA, Inc. | 323 | $212,417 |
| Roche TCRC, Inc. | 7 | $89,190 |
| Acadia Pharmaceuticals Inc | 74 | $35,499 |
| Grifols, S.A. | 8 | $23,643 |
| Kyowa Kirin, Inc. | 38 | $15,467 |
| AbbVie(2 entities) | 93 | $9,797 |
| Boston Scientific | 45 | $9,256 |
| Medtronic(2 entities) | 71 | $7,412 |
| Amneal Pharmaceuticals LLC | 22 | $7,268 |
| Merz Pharmaceuticals, LLC | 19 | $5,205 |
| MDD US Operations, LLC | 18 | $4,323 |
| Roche Products Limited | 8 | $3,685 |
| Abbott | 43 | $3,361 |
| Eisai Inc. | 11 | $1,073 |
| Supernus Pharmaceuticals, Inc. | 18 | $611 |
| Lilly USA, LLC | 11 | $557 |
| Sunovion Pharmaceuticals Inc. | 6 | $470 |
| Adamas Pharmaceuticals, Inc. | 27 | $448 |
| Novartis | 17 | $416 |
| Revance Therapeutics, Inc. | 6 | $362 |
| Acorda Therapeutics, Inc | 13 | $271 |
| UCB, Inc. | 2 | $256 |
| Catalyst Pharmaceuticals, Inc. | 2 | $248 |
| Jazz Pharmaceuticals Inc. | 2 | $247 |
| Greenwich Biosciences, Inc. | 2 | $237 |
| Insightec,inc | 1 | $168 |
| Ipsen Biopharmaceuticals, Inc | 2 | $150 |
| Pfizer | 8 | $141 |
| SK Life Science, Inc. | 1 | $122 |
| Neurelis, Inc. | 1 | $99 |
| Ricoh USA, Inc | 1 | $53 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INGREZZA$540,691
- Austedo XR$139,542
- AUSTEDO$67,372
- NUPLAZID$33,786
- ONGENTYS$24,795
- NOURIANZ$14,907
- VERCISE$6,854
- XEOMIN$4,880
- GOCOVRI$4,154
- PERCEPT PC BRAINSENSE$3,151
- UZEDY$1,614
- INFINITY$1,611
- GENERAL DBS$1,199
- Percept$1,130
- Fycompa$963
- VYALEV$947
- ONGENTYS 50MG CAPSULES 30$932
- QULIPTA$719
- PROCLAIM$598
- RECLAIM$520
How this compares
$1,443,812 in reported general payments places this provider in the 95th percentile of 652 neurology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuplazidPimavanserin Tartrate | 94 | $487,897 |
| Austedo XrDeutetrabenazine | 38 | $430,330 |
| AustedoDeutetrabenazine | 37 | $236,278 |
| IngrezzaValbenazine Tosylate | 27 | $206,579 |
| GocovriAmantadine Hcl | 43 | $118,848 |
| RytaryCarbidopa/Levodopa | 49 | $101,576 |
| Tetrabenazine | 13 | $81,706 |
| NourianzIstradefylline | 34 | $80,710 |
| NeuproRotigotine | 30 | $28,722 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 472 | $28,436 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 28 | $24,347 |
| QuliptaAtogepant | 22 | $23,096 |
| FycompaPerampanel | 14 | $18,806 |
| Entacapone | 28 | $8,009 |
| Rasagiline Mesylate | 26 | $5,652 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr, Austedo | $212,417 | $666,60875 claims |
| Acadia Pharmaceuticals IncNuplazid | $35,499 | $487,89794 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $583,294 | $206,57927 claims |
| MDD US Operations, LLCGocovri | $4,323 | $118,84843 claims |
| Amneal Pharmaceuticals LLCRytary | $7,268 | $101,57649 claims |
| Kyowa Kirin, Inc.Nourianz | $15,467 | $80,71034 claims |
| UCB, Inc.Neupro | $256 | $28,72230 claims |
| AbbVieQulipta | $9,797 | $23,09622 claims |
| Eisai Inc.Fycompa | $1,073 | $18,80614 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 652 neurology providers in Michigan.
Other neurology in Detroit
- Evanthia BernitsasDetroit$4.8M
- Mirela CerghetDetroit$3.8M
- Jacob RubeDetroit$651K
- Tobias WalbertDetroit$490K
- Andrew RussmanDetroit$488K
- Daniel NewmanDetroit$355K
- Kavita GroverDetroit$236K
- Aaron EllenbogenFarmington Hills$14.5M
- Martin BelkinFarmington Hills$5.8M
- Yang Mao DraayerFarmington Hills$4.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.